159992 创新药
已收盘 05-21 15:00:00
资讯
新帖
简况
5月21日昂利康（002940）涨停分析：业绩高增、创新药进展与宠物药放量驱动
证券之星 · 05-21 15:33
5月21日昂利康（002940）涨停分析：业绩高增、创新药进展与宠物药放量驱动
港股异动 | 诺诚健华(09969)午后涨超4% 抗炎症创新药ICP054完成首例受试者入组
智通财经 · 05-21 14:03
港股异动 | 诺诚健华(09969)午后涨超4% 抗炎症创新药ICP054完成首例受试者入组
创新药迎政策利好 富国港股通医药优选即将结束募集
新浪基金 · 05-21 11:58
创新药迎政策利好 富国港股通医药优选即将结束募集
本土创新药企迎收获期：肿瘤守阵地，慢病拓新局
21世纪经济报道 · 05-21 11:47
本土创新药企迎收获期：肿瘤守阵地，慢病拓新局
港股创新药、汽车板块携手反弹，港股通科技ETF华夏（159101）价格上扬
证券之星 · 05-21 10:03
港股创新药、汽车板块携手反弹，港股通科技ETF华夏（159101）价格上扬
众生药业：昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药
证券之星 · 05-20 20:53
众生药业：昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药
转型阵痛中的千红制药：肝素原料药周期冲击一季度业绩，创新药远水难解近渴
证券之星 · 05-20 17:00
转型阵痛中的千红制药：肝素原料药周期冲击一季度业绩，创新药远水难解近渴
华润三九：HiCM-188为全球首个在中、美两国同时获批临床默示许可的基于诱导多能干细胞的心衰再生治疗创新药
证券之星 · 05-20 16:12
华润三九：HiCM-188为全球首个在中、美两国同时获批临床默示许可的基于诱导多能干细胞的心衰再生治疗创新药
千红制药：公司创新药项目均处于科学、有序地推进临床试验进程中
证券之星 · 05-20 11:36
千红制药：公司创新药项目均处于科学、有序地推进临床试验进程中
创新药继续筑底，华宝基金药ETF、港股通创新药ETF再探历史新低！“抄底”资金狂涌，520880近10日吸金7.7亿
新浪基金 · 05-20 11:03
创新药继续筑底，华宝基金药ETF、港股通创新药ETF再探历史新低！“抄底”资金狂涌，520880近10日吸金7.7亿
【券商聚焦】招银国际：AI有望改变创新药研发范式
金吾财讯 · 05-19 13:13
【券商聚焦】招银国际：AI有望改变创新药研发范式
广药接手达安基因；阿斯利康高血压创新药获美国FDA批准
21世纪经济报道 · 05-19 08:01
广药接手达安基因；阿斯利康高血压创新药获美国FDA批准
恒瑞医药：公司已有瑞拉芙普α、瑞康曲妥珠单抗、阿得贝利单抗等多款生物制品类创新药获批上市
每日经济新闻 · 05-18
恒瑞医药：公司已有瑞拉芙普α、瑞康曲妥珠单抗、阿得贝利单抗等多款生物制品类创新药获批上市
阿里健康(00241)下跌3.54% 机构指利润或因投资于创新药、医疗AI而下滑
金吾财讯 · 05-18
阿里健康(00241)下跌3.54% 机构指利润或因投资于创新药、医疗AI而下滑
港股异动 | 创新药概念股全线下挫 全球债市抛售潮初现 高利率或冲击行业估值及融资端
智通财经 · 05-18
港股异动 | 创新药概念股全线下挫 全球债市抛售潮初现 高利率或冲击行业估值及融资端
从BD热潮到全球化稳健竞速：中国创新药“价值洼地”待破局
21世纪经济报道 · 05-18
从BD热潮到全球化稳健竞速：中国创新药“价值洼地”待破局
创新药概念走软 药明合联(02268)领跌5.57% 机构成仍看好以创新为主医药科技主线
金吾财讯 · 05-18
创新药概念走软 药明合联(02268)领跌5.57% 机构成仍看好以创新为主医药科技主线
【券商聚焦】中信建投：创新药迎盈利兑现期 国内商业化与海外授权双轮驱动业绩增长
金吾财讯 · 05-18
【券商聚焦】中信建投：创新药迎盈利兑现期 国内商业化与海外授权双轮驱动业绩增长
券商晨会精华 | 关注创新药国际化、边际改善等结构性机会
智通财经 · 05-18
券商晨会精华 | 关注创新药国际化、边际改善等结构性机会
资金悄然“换道”？港股通创新药跌出性价比，520880迅猛吸金超5亿！
新浪基金 · 05-17
资金悄然“换道”？港股通创新药跌出性价比，520880迅猛吸金超5亿！
暂无数据
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159992","market":"SZ","secType":"STK","nameCN":"创新药","latestPrice":0.793,"timestamp":1779347022000,"preClose":0.786,"halted":0,"volume":1172388923,"delay":0,"changeRate":0.0089,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":0.007,"latestTime":"05-21 15:00:00","open":0.786,"high":0.809,"low":0.785,"amount":937000000,"amplitude":0.0305,"askPrice":0.794,"askSize":6231,"bidPrice":0.793,"bidSize":11825,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779413400000},"marketStatusCode":5,"adr":0,"adjPreClose":0.786,"symbolType":"fund","openAndCloseTimeList":[[1779327000000,1779334200000],[1779339600000,1779346800000]],"highLimit":0.865,"lowLimit":0.707,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":0.352982,"marketValue":0,"turnoverRate":0,"status":0,"floatMarketCap":0},"requestUrl":"/m/hq/s/159992/tweets","defaultTab":"tweets","newsList":[{"id":"2637388893","title":"5月21日昂利康（002940）涨停分析：业绩高增、创新药进展与宠物药放量驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2637388893","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637388893?lang=zh_cn&edition=full","pubTime":"2026-05-21 15:33","pubTimestamp":1779348831,"startTime":"0","endTime":"0","summary":"证券之星消息，昂利康5月21日涨停收盘，收盘价45.65元。5月21日昂利康涨停的可能因素有：2025年归母净利润同比大增56.15%、扣非净利增78.82%，核心制剂业务营收增长超20%；定增11.2亿元获深交所受理，全部投向创新药ALK-N001Ⅰ期临床；富马酸伏诺拉生片获批双规格注册证书；宠物麻醉药批文落地且销量倍增；头孢全酶法工艺及阿莫西林技改强化原料药一体化能力。近5日资金流向一览见下表：该股为创新药，医药，化学原料药概念热股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100023617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239","159992","06978","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637041198","title":"港股异动 | 诺诚健华(09969)午后涨超4% 抗炎症创新药ICP054完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2637041198","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637041198?lang=zh_cn&edition=full","pubTime":"2026-05-21 14:03","pubTimestamp":1779343431,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华午后涨超4%，截至发稿，涨3.27%，报12.32港元，成交额9032.58万港元。消息面上，诺诚健华此前发布公告，新型口服、潜在同类最佳的IL-17AA/AF抑制剂 ICP-054 的1期临床试验完成首例受试者入组。目前，全球尚无口服IL-17抑制剂获批上市或处于后期开发阶段。ICP-054的口服小分子特性，在用药便利性、患者依从性以及临床可及性上，有潜力比目前已获批的生物制剂IL-17疗法更具优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","688428","BK1161","BK4585","BK0239","09969","VXUS","06978","BK1574","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637806569","title":"创新药迎政策利好 富国港股通医药优选即将结束募集","url":"https://stock-news.laohu8.com/highlight/detail?id=2637806569","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637806569?lang=zh_cn&edition=full","pubTime":"2026-05-21 11:58","pubTimestamp":1779335880,"startTime":"0","endTime":"0","summary":"近期，中国创新药出海再添重磅利好，恒瑞医药与BMS达成总金额约152亿美元的全球战略合作，标志着国内创新药从“出海授权”迈入“全球共创”新周期；与此同时，港版FDA计划于年底成立，内地医保目录调整同步提速，创新药产业迎来多重利好。在此背景下，富国港股通医药优选混合型证券投资基金正在发行中，并将于5月22日结束募集。该基金专注港股医药赛道，为投资者布局港股创新药龙头提供便捷通道。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-05-21/doc-inhyrrtp6358211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["VXUS","159992","06978","BK1161","BK1515","BK1574","BK4588","09939","BK4585","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637380651","title":"本土创新药企迎收获期：肿瘤守阵地，慢病拓新局","url":"https://stock-news.laohu8.com/highlight/detail?id=2637380651","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637380651?lang=zh_cn&edition=full","pubTime":"2026-05-21 11:47","pubTimestamp":1779335272,"startTime":"0","endTime":"0","summary":"当前，我国创新药产业在BD（商务拓展）出海与本土商业化放量的驱动下，产业结构加速优化，本土创新药从研发投入期转向价值收获期。日前，药智网数据显示，2025年国内创新药销售收入TOP10药企合计营收突破千亿元大关。百济神州、恒瑞医药、中国生物制药、翰森制药、信达生物迈过创新药收入百亿元门槛。同时，百济神州、信达生物更是实现扭亏为盈，打破“国产创新药只烧钱不赚钱”的魔咒。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605213744749076.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605213744749076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06978","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637980869","title":"港股创新药、汽车板块携手反弹，港股通科技ETF华夏（159101）价格上扬","url":"https://stock-news.laohu8.com/highlight/detail?id=2637980869","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637980869?lang=zh_cn&edition=full","pubTime":"2026-05-21 10:03","pubTimestamp":1779329019,"startTime":"0","endTime":"0","summary":"5月21日(周四)早盘，港股汽车、港股创新药板块携手反弹。截至9:57，港股通科技ETF华夏二级市场价格上扬，持仓股小鹏集团-W涨超6%，康方生物涨超5%，信达生物、百济神州涨超2%。逢低关注新一代港股科技底仓配置工具——港股通科技ETF华夏，被动跟踪国证港股通科技指数，覆盖硬科技+互联网+新能源汽车+生物科技，充分受益于AI产业趋势、“十五五”制造升级与数字中国双重映射、创新药出海浪潮。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026052100013011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","06978","159992","159101","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636847667","title":"众生药业：昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2636847667","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636847667?lang=zh_cn&edition=full","pubTime":"2026-05-20 20:53","pubTimestamp":1779281599,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)05月20日在投资者关系平台上答复投资者关心的问题。投资者提问：已经26年5月了，怎么看不到贵公司昂拉地韦片25年销量？股民有权知道25年每月销量吗？26年1季度销量能公布吗？众生药业回复：您好！昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药，适用于成人单纯性甲型流感患者的治疗，销售与流感季节性相关。公司正持续推进学术推广与渠道建设，后续将结合流感周期与医保落地效应，稳步推动昂拉地韦片的商业化工作。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000041340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","06978","BK1574","BK0239","002317","BK1161","BK0077","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636581718","title":"转型阵痛中的千红制药：肝素原料药周期冲击一季度业绩，创新药远水难解近渴","url":"https://stock-news.laohu8.com/highlight/detail?id=2636581718","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636581718?lang=zh_cn&edition=full","pubTime":"2026-05-20 17:00","pubTimestamp":1779267644,"startTime":"0","endTime":"0","summary":"进入2026年一季度，出口肝素原料药遭遇全球需求疲软与合同发货周期的双重打击，公司营收与归属净利润再度双双大幅下挫。2023年财报中，千红制药曾坦言，肝素原料药面临下游企业去库存、需求大幅下滑导致出口价格与数量均显著下降，行业整体受到较大冲击。对于肝素主业与创新药业务之间的战略重心如何平衡，千红制药回应称，未来将加大重大创新药物的研发与上市节奏，使之成为公司业务增长的新的战略核心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026052000030426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1574","002550","06978","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636814129","title":"华润三九：HiCM-188为全球首个在中、美两国同时获批临床默示许可的基于诱导多能干细胞的心衰再生治疗创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2636814129","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636814129?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:12","pubTimestamp":1779264739,"startTime":"0","endTime":"0","summary":"从新闻得知华润三九大举进军CGT，与深圳三院共建CGT联合实验室，打通医企研全链条转化路径，加速细胞与基因治疗产业化。华润三九积极布局细胞与基因治疗领域，已有多个在研管线，天士力已有3项CGT药物现已处于临床I期阶段，公司达成HiCM-188 项目联合研发合作，HiCM-188 为全球首个在中、美两国同时获批临床默示许可的基于诱导多能干细胞的心衰再生治疗创新药，助力公司进一步拓展细胞治疗赛道，更好地满足终末期心衰临床需求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000028293.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0060","BK0175","BK1161","BK0183","BK0196","BK0185","BK0010","06978","159992","000999","BK0028","BK0012","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636892475","title":"千红制药：公司创新药项目均处于科学、有序地推进临床试验进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2636892475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636892475?lang=zh_cn&edition=full","pubTime":"2026-05-20 11:36","pubTimestamp":1779248185,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药05月20日在投资者关系平台上答复投资者关心的问题。公司创新药项目均处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000019084.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159992","06978","002550","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636894763","title":"创新药继续筑底，华宝基金药ETF、港股通创新药ETF再探历史新低！“抄底”资金狂涌，520880近10日吸金7.7亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2636894763","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636894763?lang=zh_cn&edition=full","pubTime":"2026-05-20 11:03","pubTimestamp":1779246180,"startTime":"0","endTime":"0","summary":"5月20日，AH创新药再度走低，重仓A股创新药的药ETF华宝、100%创新药研发标的——港股通创新药ETF华宝场内价格再刷历史新低。港股通创新药ETF华宝跌逾1.5%，持续溢价交易。 场内价格迭创新低之际，520880迎来资金密集增仓。截至上日，520880近10日内有9日吸金，金额合计超7.7亿元，最新份额升至58.9亿份新高。自去年9月中旬进入阶段调整期，截至5月19日，港股通创新药ETF华宝标的指数区间累计跌幅超过30%，调整充分，估值风险释放到位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-05-20/doc-inhyphnk2640560.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","FDN","BK1574","159992","06978","159316","BK4550","BK4585","VXUS","BK4588","520880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636030884","title":"【券商聚焦】招银国际：AI有望改变创新药研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2636030884","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636030884?lang=zh_cn&edition=full","pubTime":"2026-05-19 13:13","pubTimestamp":1779167581,"startTime":"0","endTime":"0","summary":"当前，监管框架持续完善，传统药企与AI原生公司加速合作，AI制药正处于从研发提效工具迈向创新药研发范式重构的转折期。AI重构药物研发全链条，早期效率红利已率先显现。传统创新药研发长期受困于高成本、长周期和低成功率，AI技术正在改变靶点发现、分子筛选与优化等关键环节的研发范式。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981743","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","01801","LU0326950275.SGD","01177","LU1152091168.USD","LU0348827113.USD","LU1226288170.HKD","LU0634319403.HKD","LU1993786604.SGD","LU2097828631.EUR","LU1226287792.SGD","06160","LU0067412154.USD","IE00B031HY20.USD","09688","LU0456846285.SGD","LU0572944931.SGD","09926","LU0516422952.EUR","LU1719994722.HKD","02616","06978","BK1161","159992","LU1152091754.HKD","LU1880383366.USD","SG9999002562.SGD","ARTY","LU1303224171.USD","09995","AGIX","LU0072913022.USD","01093","LU1960683339.HKD","02142","IE00BPRC5H50.USD","LU0315179316.USD","BK1583","BK1588","02269","LU0348767384.USD","AIPO","LU0856984785.SGD","LU0140636845.USD","LU0456827905.SGD","01877","CHAT","LU0417516738.SGD","06185","LU0561508036.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636700080","title":"广药接手达安基因；阿斯利康高血压创新药获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636700080","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636700080?lang=zh_cn&edition=full","pubTime":"2026-05-19 08:01","pubTimestamp":1779148914,"startTime":"0","endTime":"0","summary":"政策动向2026年医保目录调整新增预申报允许商保创新药申报医保目录国家医保局介绍2026年国家医保药品目录及商业健康保险创新药品目录调整工作安排，包括首次允许纳入2025年商保创新药目录的药品申报国家医保目录，新增“预申报”环节等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605193741160824.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605193741160824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2417539215.USD","LU2236285917.USD","BK1161","LU0058720904.USD","LU2237443549.SGD","159992","BK0028","BK0122","LU2237443382.USD","LU2237443895.HKD","BK0168","LU2462157665.USD","BK0239","LU0109394709.USD","LU1829250122.USD","LU2237443978.SGD","BK0046","06978","BK0159","LABU","LU2456880835.USD","002030","LU2237443622.USD","BK4568","BK4588","LU2237443465.HKD","LU0889565916.HKD","BK0042","LU0320765992.SGD","BK1574","BK0188","AZNH","BK4007","BK4585","LU0289739699.SGD","AZN","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636026816","title":"恒瑞医药：公司已有瑞拉芙普α、瑞康曲妥珠单抗、阿得贝利单抗等多款生物制品类创新药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2636026816","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636026816?lang=zh_cn&edition=full","pubTime":"2026-05-18 16:48","pubTimestamp":1779094139,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：你好，贵司2025年新成立的生物制药事业部，请问在生物制药方面有什么新的进展？","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605183740505938.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605183740505938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IPOS","LU1655091616.SGD","LU2097828474.EUR","LU1997245177.USD","LU0359202008.SGD","BK1161","LU1023057109.AUD","BK0012","LU0405327494.USD","LU2580892862.HKD","LU2488822045.USD","600276","LU2580892789.USD","LU2328871848.SGD","01276","LU2097828631.EUR","LU2097828714.EUR","LU1997245094.SGD","BK0188","BK0183","159992","LU0405327148.USD","LU2097828557.USD","LU1255011170.USD","LU2148510915.USD","LU1146622755.USD","LU1064131003.USD","BK0060","LU1328615791.USD","LU1820825898.SGD","LU1064130708.USD","BK0028","BK1191","LU1969619763.USD","LU0359201612.USD","LU2543165471.USD","LU2289578879.USD","LU1781817850.SGD","06978","LU2097828805.USD","LU0359201885.HKD","LU1997244956.HKD","BK0196","LU1580142542.USD","LU2495084118.USD","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636428420","title":"阿里健康(00241)下跌3.54% 机构指利润或因投资于创新药、医疗AI而下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2636428420","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636428420?lang=zh_cn&edition=full","pubTime":"2026-05-18 14:00","pubTimestamp":1779084049,"startTime":"0","endTime":"0","summary":"金吾财讯 | 阿里健康 跌超3%，截止发稿，最新报4.10港元，下跌3.54%，成交额4.87亿港元。消息面上，里昂研究认为，阿里健康26财年下半年收入略低于预期，但利润大致符合预期。该行认为，创新药继续是阿里健康的战略增长动力，但利润或会因持续投资于创新药和医疗人工智能而下跌。里昂下调阿里健康2027至2028财年经调整净利润预测23%，目标价相应由5.3港元下调至4.7港元，对应潜在升幅11%。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981614","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","BK1161","BK1589","BK1591","BK1615","00241","BK1571","159992","BK1584","BK1610","BK1189","BK1247","BK1502","BK1142","150261","BK1574","BK1501","BK1515","BK1617","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636046305","title":"港股异动 | 创新药概念股全线下挫 全球债市抛售潮初现 高利率或冲击行业估值及融资端","url":"https://stock-news.laohu8.com/highlight/detail?id=2636046305","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636046305?lang=zh_cn&edition=full","pubTime":"2026-05-18 11:38","pubTimestamp":1779075485,"startTime":"0","endTime":"0","summary":"消息面上，霍尔木兹海峡持续封锁，正推动油价攀升至每桶105美元以上。全球债券市场抛售潮征兆已现。美国10年期国债收益率升至4.5%以上，日本30年期国债收益率首次突破4%，英国长期国债收益率则升至28年来的最高水平，引发市场对于未来全球金融环境趋紧的担忧。其中，4 月全球、美国、国内创新药投融资均呈现强劲复苏的态势。但也有分析人士指出，若全球利率环境进入更高水平且持续，将冲击创新药行业估值及融资端。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442779.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1585","06978","BK4585","BK1587","09141","02171","02137","09966","BK4588","159992","BK1515","BK1574","09939","VXUS","03141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636045071","title":"从BD热潮到全球化稳健竞速：中国创新药“价值洼地”待破局","url":"https://stock-news.laohu8.com/highlight/detail?id=2636045071","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636045071?lang=zh_cn&edition=full","pubTime":"2026-05-18 11:14","pubTimestamp":1779074040,"startTime":"0","endTime":"0","summary":"当下，全球生物医药行业正经历一场深刻的周期重构。在资本寒冬余波未尽与监管政策动态调整的交织影响下，中国创新药企正从过去“跟随式”创新的角色，迈向全球创新“发源地”的关键转型期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605183740183766.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605183740183766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","159992","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636048086","title":"创新药概念走软 药明合联(02268)领跌5.57% 机构成仍看好以创新为主医药科技主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2636048086","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636048086?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:09","pubTimestamp":1779070152,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念整体走软，截至发稿，药明合联 跌5.57%，亚盛医药-B跌5.50%，四环医药跌4.55%，康方生物跌4.49%，歌礼制药-B跌4.36%，同源康医药-B跌4.31%，康诺亚-B跌4.24%，荣昌生物跌4.14%。展望2026年，该机构继续看好以创新为主的医药科技主线，重点关注创新药、脑机接口、AI医疗、手术机器人等，同时建议布局2026年行业有望迎来反转的老龄化及院外消费，关注估值较低的麻药、血制品、中药等。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981521","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","LU0348784397.USD","BK1191","BK1141","LU1794554557.SGD","BK1593","02162","IE00BPRC5H50.USD","LU0540923850.HKD","159938","09926","LU2399975544.HKD","LU0348825331.USD","LU0417516738.SGD","BK1583","LU0348735423.USD","LU0348767384.USD","LU0348827113.USD","BK1574","LU1961090484.USD","LU0634319403.HKD","LU0348783233.USD","LU0561508036.HKD","LU2476274308.USD","LU2328871848.SGD","BK1161","LU1969619763.USD","IE00B5MMRT66.SGD","LU0348766576.USD","00460","09995","LU2778985437.USD","LU0417516902.SGD","LU2476274720.SGD","09939","BK1515","02268","BK1600","06855","IE00B543WZ88.USD","LU1720050803.USD","LU2488822045.USD","BK1587","02410","06978","01672","LU0417516571.SGD","SG9999014674.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636483820","title":"【券商聚焦】中信建投：创新药迎盈利兑现期 国内商业化与海外授权双轮驱动业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2636483820","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636483820?lang=zh_cn&edition=full","pubTime":"2026-05-18 09:32","pubTimestamp":1779067963,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业触底回暖，创新药迎来盈利兑现期，国内商业化与海外授权双轮驱动业绩增长，多家企业扭亏。26Q1对外授权总额超600亿美元，ADC、双抗等前沿赛道交易持续火热。2026年ASCO年会94项中国研究中选口头报告，依沃西单抗登上全体大会，标志着中国创新药全球学术影响力迈上新台阶。国内支付端医保谈判与商保目录合力支持真创新。建议关注创新药国际化、边际改善等结构性机会。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981512","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185","IE00B543WZ88.USD","09926","02269","01177","IE00BZ08YR35.GBP","01093","601066","LU0039217434.USD","LU0348827113.USD","LU1303224171.USD","IE00BZ08YT58.USD","159992","LU1152091168.USD","02616","BK1141","IE00B0JY6N72.USD","LU1242518857.USD","LU0561508036.HKD","LU0979878070.USD","06160","LU0516423174.USD","LU2097828557.USD","LU1242518931.SGD","LU0516422952.EUR","BK1574","LU0326950275.SGD","LU1152091754.HKD","09995","06978","01877","LU1688375341.USD","09688","BK1588","LU1969619763.USD","LU2399975544.HKD","BK1161","LU2097828474.EUR","LU2097828631.EUR","LU1226287875.USD","LU1993786604.SGD","LU0456827905.SGD","LU0588546209.SGD","02142","LU0359202008.SGD","LU0417516738.SGD","01801","IE00B5MMRT66.SGD","IE00BZ08YS42.EUR","SG9999002562.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636017909","title":"券商晨会精华 | 关注创新药国际化、边际改善等结构性机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2636017909","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636017909?lang=zh_cn&edition=full","pubTime":"2026-05-18 08:31","pubTimestamp":1779064269,"startTime":"0","endTime":"0","summary":"在今日券商晨会上，中信建投认为，关注创新药国际化、边际改善等结构性机会。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260518/20260518083143_48238.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260518/20260518083143_48238.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1442690.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhitongcaijing_hushen_highlight","symbols":["BK1161","BK1574","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636092964","title":"资金悄然“换道”？港股通创新药跌出性价比，520880迅猛吸金超5亿！","url":"https://stock-news.laohu8.com/highlight/detail?id=2636092964","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636092964?lang=zh_cn&edition=full","pubTime":"2026-05-17 19:46","pubTimestamp":1779018360,"startTime":"0","endTime":"0","summary":"5月15日，大市深度调整，港股通创新药继续下行，康方生物、信达生物、百济神州、石药集团、中国生物制药等权重龙头普跌。100%创新药研发标的——港股通创新药ETF华宝放量收跌2.14%四连阴，场内价格直逼历史低点。 本周，港股通创新药ETF华宝累跌6.91%，周线收出四连阴。截至5月14日，港股通创新药ETF华宝近10日累计获超5.35亿元净申购，基金份额亦水涨船高，升至53.42亿份新高！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-05-17/doc-inhyfhfe4569000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","159992","06978","VXUS","BK4585","BK4588","520880"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779393640110,"stockEarnings":[{"period":"1week","weight":-0.0125},{"period":"1month","weight":-0.0469},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0736},{"period":"1year","weight":0.0352},{"period":"ytd","weight":-0.0457}],"compareEarnings":[{"period":"1week","weight":-0.0241},{"period":"1month","weight":-0.0019},{"period":"3month","weight":-0.0012},{"period":"6month","weight":0.0632},{"period":"1year","weight":0.2036},{"period":"ytd","weight":0.0273}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创新药,159992,创新药股票,创新药股票老虎,创新药股票老虎国际,创新药行情,创新药股票行情,创新药股价,创新药股市,创新药股票价格,创新药股票交易,创新药股票购买,创新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}